At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 323 enrolled
Drug / intervention
GSK2340274A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
In Brief
A Phase 2 clinical trial evaluating GSK2340274A and GSK2340273A for Influenza. Completed, enrolled 323 participants across 30 sites in 2 countries.
Detailed Summary
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age. This Protocol Posting has been updated following the Protocol amendment 1 \& 2, September and October 2009. The sections impacted are study design, objectives and analysis methods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionMar 2011
TodayJul 2026
First PostedSep 14, 2009
Enrollment StartOct 20, 2009
Primary CompletionMar 21, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.8 years ago
Interventions
GSK2340274Abiological
Two intramuscular injections
GSK2340273Abiological
Two intramuscular injections